AzTrials
AzTrials

Senile Dementia, Alzheimer TypePhase 4NCT00208819

A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

A Phase 4 study testing risperidone, quetiapine and olanzapine in people with Senile Dementia, Alzheimer Type and Dementia, Alzheimer Type, run by Emory University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with dementia. Read more about this study

Who is it for?
Ages 65 years and older
What is being tested?
risperidone, quetiapine and olanzapine
How many people
50 participants
Where
1 siteUnited States
Study dates
Sep 2003to Jul 2007
Phase
Phase 4

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • inpatients admitted to Wesley Woods Inpatient service for Dementia with psychosis and agitation; taking risperidone (up to 1.5 mg/day), quetiapine (up to 175 mg/day), or olanzapine (up to 7.5 mg/day)

Who cannot join

  • prior sensitivity to risperidone, quetiapine, olanzapine or divalproex

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Wesley Woods Geriatric Hospital

    Atlanta, Georgia, 30329

Other trials in United States

About this study

Official title: Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies

The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with dementia.

Read the detailed description

Previous researchers have attempted to establish a "target dose" for antipsychotic medications (such as risperidone, quetiapine, or olanzapine) in treating symptoms of agitation in dementia. They have tried to identify the dose with the best risk-benefit ratio for patients considering the significant side effects the medications can cause. Patients taking the doses identified respond only partially and continue to experience some symptoms of agitation, however. One study showed that in patients whose agitation symptoms were not adequately controlled by the target dose of an antipsychotic medication alone, the addition of divalproex further improved behavior in 72% of patients.

The goal of this study is to compare two standard therapies for the management of agitation symptoms in dementia patients. Subjects in this study will include patients who are admitted to the Wesley Woods Inpatient service for the treatment for dementia complicated by behavioral symptoms. After a patient reaches the target dose of risperidone (up to 1.5 mg/day), quetiapine (up to 175 mg/day), or olanzapine (up to 7.5 mg/day) and agitation symptoms are still not adequately managed, he or she will be randomized to one of two groups. Group 1 participants will continue to receive increasing doses of antipsychotic medication until symptoms are controlled or he or she is unable to tolerate the dose. Group 2 participants will continue to receive the target dose of antipsychotic medication and also receive increasing doses of divalproex until symptoms are controlled or he or she is unable to tolerate the dose. Patients will be evaluated at 4 time points during hospitalization. Patients will be evaluated using scales that measure changes in cognition, function, and behavior. Laboratory and ECG results, and scales testing for movement disorders will be done to monitor safety. The family will then be contacted about 3 months the patient's hospitalization to assess current treatment status, residential status, and health status.

Being tested
risperidone, quetiapine, olanzapine, divalproex
Keywords
Alzheimer's Disease, Geriatric, Dementia, Agitation, Behavioral Disturbances, Psychosis
Medical subject headings
Alzheimer Disease, Dementia, Psychomotor Agitation, Mental Disorders, Psychotic Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pittsburgh Agitation Scale (PAS)

  2. DiMarco Rating Scale for Extrapyramidal Symptoms

  3. UKU side effect rating scale:autonomic subscale

  4. Behavioral Activity Rating Scale (BARS)

  5. Visual Analog Scale for Nighttime Sleep and Daytime drowsiness (VAS)

  6. Confusion Assessment Method (CAM)

  7. Mini-Mental State Exam (MMSE)

  8. Cohen-Mansfield Agitation Inventory

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2005 (estimated)
  2. Study startSep 2003
  3. Study completionJul 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00208819
Sponsor's protocol ID
0673-2003
Status last verified
Nov 2013
First submitted
13 Sep 2005
Last updated
13 Nov 2013
Results posted
No

Publications

  • Tune L. Management of Noncognitive Symptoms of Dementia. Essentials of Clinical Psychopharmacology, 2nd ed. 2001: 935-948.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in